FDA plans priority vouchers for firms supporting ‘national interests’

The US Food and Drug Administration has announced the Commissioner’s National Priority Voucher (CNPV) program aimed at enhancing the health interests of Americans.

This voucher may be redeemed by drug developers to participate in a novel priority program by the FDA and shortens its review time from approximately 10 to 12 months to just one to two months, following a sponsor’s final drug application submission.

The new CNPV process convenes experts from FDA offices for a team-based review, rather than using the standard review system of a drug application being sent to numerous FDA offices.